0.05Open0.30Pre Close6 Volume460 Open Interest5.00Strike Price45.00Turnover97.06%IV19.44%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.3193Delta0.3248Gamma21.35Leverage Ratio-0.0079Theta0.0008Rho6.82Eff Leverage0.0040Vega
Fate Therapeutics Stock Discussion
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
Fate Therapeutics, a clinical-stage biopharmaceutical company focusing on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, announced their participation in the 2024 Jefferies Global Healthcare Conference. The presentation is scheduled for June 5, 2024, at 3:00 PM ET in New York. The event will be webcasted live and accessible on the Company’s website, with an arch...
NEWS
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...
Dow Jones· 1 min ago
No comment yet